The University of Texas MD Anderson Cancer Center
Houston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Thyroid cancer
What is new in Thyroid cancer research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AbirateronePhase 3 · NCT07620574
- AL2846 CapsulesPhase 3 · NCT06860971
- Artificial Tears MethylcellulosePhase 3 · NCT05999630
- AtezolizumabPhase 3 · NCT07620574 · NCT03181100 · NCT03170960
- CabozantinibPhase 3 · NCT07620574 · NCT03170960 · NCT06482086 · NCT06475989 · NCT02867592 · NCT04211337 · NCT03690388
- DabrafenibPhase 3 · NCT01947023 · NCT02465060 · NCT04544111 · NCT04940052 · NCT07440290 · NCT07886905 · NCT04675710 · NCT06475989 · NCT04238624
- desiccated thyroid extract (DTE)+levothyroxine (L-T4)Phase 3 · NCT07239674
- EnzalutamidePhase 3 · NCT07620574
- I131Phase 3 · NCT01837745
- Intraoperative Injection of Carbon NanoparticlesPhase 3 · NCT06791005
- LevothyroxinePhase 3 · NCT05316922
- metforminPhase 3 · NCT05468554
- Modified delineationPhase 3 · NCT06752239
- NivolumabPhase 3 · NCT07620574 · NCT02465060 · NCT03914300 · NCT04514484 · NCT04061980 · NCT02834013 · NCT06638931 · NCT03449108 · NCT05696548
- PrednisonePhase 3 · NCT07620574
- Preoperative Injection of Carbon NanoparticlesPhase 3 · NCT06791005
- Radioactive iodine (I-131)Phase 3 · NCT05468554
- rhTSH stimulationPhase 3 · NCT01837745
- SelpercatinibPhase 3 · NCT04759911 · NCT03899792 · NCT04280081 · NCT04211337
- Standard delineationPhase 3 · NCT06752239
- Systematic RAI-treatmentPhase 3 · NCT04290663
- TrametinibPhase 3 · NCT02465060 · NCT03085056 · NCT05907304 · NCT04544111 · NCT04940052 · NCT07440290 · NCT07886905 · NCT04675710 · NCT06475989 · NCT04238624 · NCT05275374 · NCT02152995
- VandetanibPhase 3 · NCT06482086 · NCT04211337
- ZanzalintinibPhase 3 · NCT07620574 · NCT07470489 · NCT06959511 · NCT06959641
- CobimetinibPhase 2/3 · NCT03181100 · NCT05768178 · NCT06440850
- Dexmedetomidine Injection [Precedex]Phase 2/3 · NCT07434206
- I131 1.1 GBqPhase 2/3 · NCT01398085
- VemurafenibPhase 2/3 · NCT03181100 · NCT05768178 · NCT06440850
- 131I TherapyPhase 2 · NCT06458036 · NCT05783323
- AdavosertibPhase 2 · NCT02465060
- AfatinibPhase 2 · NCT02465060
- Afatinib DimaleatePhase 2 · NCT02465060
- AldesleukinPhase 2 · NCT03449108
- AnlotinibPhase 2 · NCT06482086
- Anlotinib and BenmelstobartPhase 2 · NCT07193186
- Anti-PD-1 Inhibitor (Continuation of Prior Treatment)Phase 2 · NCT07874321
- ApatinibPhase 2 · NCT06482086
- APL-101 Oral CapsulesPhase 2 · NCT03175224
- Autologous Tumor Infiltrating Lymphocytes LN-145Phase 2 · NCT03449108
- Autologous Tumor Infiltrating Lymphocytes LN-145-S1Phase 2 · NCT03449108
- AvutometinibPhase 2 · NCT06007924
- Becotatug Vedotin (MRG003)Phase 2 · NCT07874321
- BevacizumabPhase 2 · NCT03181100
- BinimetinibPhase 2 · NCT02465060 · NCT05355701 · NCT04061980
- Cabozantinib S-malatePhase 2 · NCT03914300 · NCT04514484 · NCT02867592
- Camrelizumab combination with ApatinibPhase 2 · NCT04560127
- CapivasertibPhase 2 · NCT02465060
- CemiplimabPhase 2 · NCT06902376 · NCT07470489
- comprehensive coverage radiotherapyPhase 2 · NCT07777536
- CopanlisibPhase 2 · NCT02465060
- Copanlisib HydrochloridePhase 2 · NCT02465060
- CrizotinibPhase 2 · NCT02465060
- CyclophosphamidePhase 2 · NCT04877613 · NCT04119024 · NCT03099356 · NCT03449108
- Cyclophosphamide+Doxorubicin+5-FluorouracilPhase 2 · NCT06713057
- Cyclophosphamide+Pemetrexed+5-FluorouracilPhase 2 · NCT06713057
- Dabrafenib + TrametinibPhase 2 · NCT06482086
- Dabrafenib MesylatePhase 2 · NCT01947023 · NCT02465060 · NCT04439292
- dabrafenib/trametinibPhase 2 · NCT06079333
- DasatinibPhase 2 · NCT02465060
- DefactinibPhase 2 · NCT02465060 · NCT06007924
- Defactinib HydrochloridePhase 2 · NCT02465060
- DocetaxelPhase 2 · NCT03360890
- Docetaxel + DoxorubicinPhase 2 · NCT06713057
- DOMVANALIMAB + ZIMBERELIMABPhase 2 · NCT06790706
- DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4Phase 2 · NCT06790706
- Donafeib with SintilimabPhase 2 · NCT06787911
- DonafenibPhase 2 · NCT06482086
- Doxorubicin + CisplatinPhase 2 · NCT06713057
- Doxorubicin + Cyclophosphamide + CisplatinPhase 2 · NCT06713057
- EncorafenibPhase 2 · NCT04061980
- Enfortumab VedotinPhase 2 · NCT07863765
- EntrectinibPhase 2 · NCT06482086 · NCT02650401 · NCT02568267
- ErdafitinibPhase 2 · NCT02465060
- EthosPhase 2 · NCT07886905
- EverolimusPhase 2 · NCT06482086 · NCT02143726
- FexagratinibPhase 2 · NCT02465060
- FludarabinePhase 2 · NCT04877613 · NCT03449108
- Gemcitabine alonePhase 2 · NCT06713057
- I-131Phase 2 · NCT03841617
- Immunotherapy combined with Multikinase inhibitors in neoadjuvant treatmentPhase 2 · NCT06848920
- Intensity-Modulated Radiation TherapyPhase 2 · NCT04675710
- Iodine I-131Phase 2 · NCT06440850 · NCT02152995
- Iodine-124Phase 2 · NCT06961084 · NCT03647358
- IpatasertibPhase 2 · NCT02465060
- IpilimumabPhase 2 · NCT03914300 · NCT02834013 · NCT03449108
- LarotrectinibPhase 2 · NCT02465060 · NCT06482086
- Larotrectinib monotherapyPhase 2 · NCT05783323
- Larotrectinib SulfatePhase 2 · NCT02465060
- LenvatinibPhase 2 · NCT07092514 · NCT06482086 · NCT04171622 · NCT07874321 · NCT05696548
- Levothyroxine Oral Tablet [Synthroid]Phase 2 · NCT06790589
- Lu-177 DOTATATE (Lutathera®)Phase 2 · NCT06121271
- MRG003 in combination with pucotenlimabPhase 2 · NCT07235566
- Nab-paclitaxelPhase 2 · NCT03181100 · NCT05786924
- OsimertinibPhase 2 · NCT02465060
- PaclitaxelPhase 2 · NCT03181100 · NCT03085056
- Paclitaxel + CarboplatinPhase 2 · NCT06713057
- Paclitaxel + CisplatinPhase 2 · NCT06713057
- Paclitaxel + DoxorubicinPhase 2 · NCT06713057
- PalbociclibPhase 2 · NCT02465060
- PDR001Phase 2 · NCT04544111
- PembrolizumabPhase 2 · NCT05852223 · NCT05119296 · NCT07886905 · NCT04675710 · NCT03360890 · NCT04171622 · NCT02628067
- Pembrolizumab + LenvatinibPhase 2 · NCT06374602
- PertuzumabPhase 2 · NCT02465060
- PI3K-beta Inhibitor GSK2636771Phase 2 · NCT02465060
- PlixorafenibPhase 2 · NCT05503797
- PralsetinibPhase 2 · NCT06482086
- Pulsed Stereotactic Ablative RadiotherapyPhase 2 · NCT07886905
- Recombinant Thyrotropin AlfaPhase 2 · NCT06440850
- RelatlimabPhase 2 · NCT02465060
- Sacituzumab govitecanPhase 2 · NCT06923826 · NCT06235216
- Sacituzumab TirumotecanPhase 2 · NCT07521670
- SapanisertibPhase 2 · NCT02465060
- Selective coverage radiotherapyPhase 2 · NCT07777536
- Selpercatinib MonotherapyPhase 2 · NCT06458036
- SirolimusPhase 2 · NCT03099356
- SorafenibPhase 2 · NCT06482086 · NCT02143726
- sorafenib with everolimusPhase 2 · NCT01141309
- SpartalizumabPhase 2 · NCT04802876
- ST-1898 tabletsPhase 2 · NCT06359847
- Stereotactic RadiosurgeryPhase 2 · NCT02713269
- Sunitinib MalatePhase 2 · NCT02465060
- TaselisibPhase 2 · NCT02465060
- ThyrogenPhase 2 · NCT03841617
- ThyroxinePhase 2 · NCT06087068
- TipifarnibPhase 2 · NCT04284774
- TislelizumabPhase 2 · NCT04802876
- Trametinib Dimethyl SulfoxidePhase 2 · NCT04439292
- TrastuzumabPhase 2 · NCT02465060
- Trastuzumab EmtansinePhase 2 · NCT02465060
- TunlametinibPhase 2 · NCT06970353
- Tunlametinib+PD-1 mAbPhase 2 · NCT06970353
- UlixertinibPhase 2 · NCT02465060
- Vemurafenib (All Groups)Phase 2 · NCT01709292
- Vemurafenib (Post Surgery) - Group A + CPhase 2 · NCT01709292
- Vindesine + CisplatinPhase 2 · NCT06713057
- VismodegibPhase 2 · NCT02465060
- 177Lu-DOTA-EB-TATEPhase 1/2 · NCT06991738
- ARV-806Phase 1/2 · NCT07023731
- Carbon Nanoparticle-Loaded IronPhase 1/2 · NCT07433283
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe]Phase 1/2 · NCT07433283
- CetuximabPhase 1/2 · NCT05786924 · NCT05355701
- Concurrent Radiation TherapyPhase 1/2 · NCT06814496
- FOLFIRIPhase 1/2 · NCT05786924
- FOLFOX6/FOLFOX7Phase 1/2 · NCT05786924
- GemcitabinePhase 1/2 · NCT04521686 · NCT05786924 · NCT03093909
- LOXO-292Phase 1/2 · NCT03157128
- MDX2001Phase 1/2 · NCT06239194
- NKG2D CAR-NK with PD-1 AntibodyPhase 1/2 · NCT06856278
- Oral repotrectinib (TPX-0005)Phase 1/2 · NCT03093116
- PanitumumabPhase 1/2 · NCT05786924
- Radioactive Iodine TherapyPhase 1/2 · NCT07453225
- S241656Phase 1/2 · NCT05786924
- Sequential Radiation therapyPhase 1/2 · NCT06814496
- TarlatamabPhase 1/2 · NCT06814496
- XP-102Phase 1/2 · NCT05275374
- [211At]NaAtPhase 1 · NCT07287748
- 1 MBq/k of 211At-MABG FractionatedPhase 1 · NCT07661420
- 177Lu-CTR-FAPI therapyPhase 1 · NCT07438847
- 177Lu-PP-F11NPhase 1 · NCT02088645
- 2 MBq/k1 of 211At-MABG FractionatedPhase 1 · NCT07661420
- 225Ac-ETN029Phase 1 · NCT07006727
- 4 MBq/k of 211At-MABG FractionatedPhase 1 · NCT07661420
- ACC-1898Phase 1 · NCT07252661
- AIC100 CAR T CellsPhase 1 · NCT04420754
- BrodalumabPhase 1 · NCT06673329
- CisplatinPhase 1 · NCT04521686
- Combination treatment (CXRPT) of external beam radiation (XRT) plus radioactive iodine (RAI)Phase 1 · NCT04892303
- DEG6498Phase 1 · NCT07244835
- DurvalumabPhase 1 · NCT04521686
- Fludarabine PhosphatePhase 1 · NCT04119024
- fluorouracilPhase 1 · NCT05355701
- Hyperpolarized Carbon C 13 PyruvatePhase 1 · NCT04589624
- IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM CellsPhase 1 · NCT04119024
- JZP815Phase 1 · NCT05557045
- LapatinibPhase 1 · NCT01947023
- Lapatinib DitosylatePhase 1 · NCT01947023
- leucovorinPhase 1 · NCT05355701
- LY3410738Phase 1 · NCT04521686
- midazolamPhase 1 · NCT05355701
- NaporafenibPhase 1 · NCT05907304
- OlaparibPhase 1 · NCT03162627
- oxaliplatinPhase 1 · NCT05355701
- Personalised treatmentPhase 1 · NCT07485569
- PF-07799544Phase 1 · NCT05538130
- PF-07799933Phase 1 · NCT05355701 · NCT05538130
- SelumetinibPhase 1 · NCT03162627
- single dose of CART-GFRa4 cellsPhase 1 · NCT04877613
- SNH-118110 Soft CapsulesPhase 1 · NCT07649200
- TH1902Phase 1 · NCT04706962
- XL092Phase 1 · NCT06902376
- [177Lu]Lu-AKIR001Early phase 1 · NCT06639191
- 177Lu-LNC1004 InjectionEarly phase 1 · NCT06898437
- Durvalumab (Medi4736)Early phase 1 · NCT03215095
- INN805Early phase 1 · NCT07459283
- Radioiodine (RAI)Early phase 1 · NCT03215095
Closest to patients
- A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaPhase 3 trial: AL2846 CapsulesThe Second Affiliated Hospital Of GXUST · Liuzhou, China + 34 more hospitalsPhase 3Results expected 2027
- Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTCPhase 3 trial: desiccated thyroid extract (DTE)+levothyroxine (L-T4)West China Hospital (sponsor)Phase 3Results expected 2027
- Trop2-targeted immunoPET Imaging of Solid TumorsPhase 2/3 trial: Thyroid cancerRenji Hospital, School of Medicine, Shanghai Jiao Tong University · Shanghai, ChinaPhase 2/3Results expected 2027
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Association and causality between breast cancer subtypes and papillary thyroid carcinoma: evidence from a clinical cohort and Mendelian randomization.
Association and causality between breast cancer subtypes and papillary thyroid carcinoma: evidence from a clinical cohort and Mendelian randomization.
Ginekologia polska
PubMed · PMID 42986727Publication
Ultrasound Pattern-Based Malignancy Risk Stratification and Subcategorization of K-TIRADS Intermediate-Suspicion Thyroid Nodules to Improve Biopsy Decision-Making.
Ultrasound Pattern-Based Malignancy Risk Stratification and Subcategorization of K-TIRADS Intermediate-Suspicion Thyroid Nodules to Improve Biopsy Decision-Making.
Korean journal of radiology
PubMed · PMID 42984201Publication
A Key Biomarker lnc-ABCA12-5:2 Compensating Diagnostic Deficiencies for Indeterminate Thyroid Nodules and Genetically Wild-Type Thyroid Malignancies.
A Key Biomarker lnc-ABCA12-5:2 Compensating Diagnostic Deficiencies for Indeterminate Thyroid Nodules and Genetically Wild-Type Thyroid Malignancies.
Oncology research
PubMed · PMID 42985401Publication
Associations of fasting blood glucose and the triglyceride-glucose index with aggressive pathological features of papillary thyroid carcinoma.
Associations of fasting blood glucose and the triglyceride-glucose index with aggressive pathological features of papillary thyroid carcinoma.
Frontiers in endocrinology
PubMed · PMID 42984499Case report
Incidental Detection of Bilateral Node-Positive Papillary Thyroid Carcinoma During Initial Staging for Localized Testicular Seminoma: A Case Report.
Incidental Detection of Bilateral Node-Positive Papillary Thyroid Carcinoma During Initial Staging for Localized Testicular Seminoma: A Case Report.
Cureus
PubMed · PMID 42985436
Organisations that can help
Helplines, patient groups and support services for you and your family.
Select your country to see the organisations there, starting with the ones closest to you.
Umbrella organisations (they connect national groups)
European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
Visit site: European Cancer Patient Coalition (ECPC)
Thyroid Federation International
Global federation of thyroid patient organisations (all thyroid conditions, incl. some thyroid cancer groups): awareness week, congress, newsletters, webinars
Visit site: Thyroid Federation International
General support
For anyone who is ill, whatever the disease: patients' rights and legal aid, crisis lines, hospice and palliative care, care in another EU country, and patient organisations' umbrella bodies.
International
European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)
International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Thyroid cancer work.
Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Shanghai Jiao Tong University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Memorial Sloan Kettering Cancer Center
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Fudan University
Shanghai, China
Team details appear once the team leader joins.
Is this your team? Claim it
Seoul National University
Seoul, South Korea
Team details appear once the team leader joins.
Is this your team? Claim it
Sichuan University
Chengdu, China
Team details appear once the team leader joins.
Is this your team? Claim it
Zhejiang University
Hangzhou, China
Team details appear once the team leader joins.
Is this your team? Claim it
West China Hospital of Sichuan University
Chengdu, China
Team details appear once the team leader joins.
Is this your team? Claim it
Central South University
Changsha, China
Team details appear once the team leader joins.
Is this your team? Claim it